🔗 Visit the ClinicalTrials.gov page for NCT01240460
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. | Oncotarget | 2012 | 1.96 |
| 2 | Current clinical development of PI3K pathway inhibitors in glioblastoma. | Neuro Oncol | 2012 | 1.33 |
| 3 | PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. | Oncotarget | 2016 | 1.02 |
| 4 | Unique biology of gliomas: challenges and opportunities. | Trends Neurosci | 2012 | 0.87 |
| 5 | The mTOR signaling pathway as a treatment target for intracranial neoplasms. | Neuro Oncol | 2014 | 0.84 |
| 6 | Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. | Clin Cancer Res | 2014 | 0.83 |
| 7 | Seizures and gliomas - towards a single therapeutic approach. | Nat Rev Neurol | 2016 | 0.83 |
| 8 | Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. | Neuro Oncol | 2015 | 0.75 |